Novo Nordisk A/S
European pharma is spared worst-case U.S. tariffs. Investors still don’t trust the deal
European pharmaceutical firms gained some much-desired clarity on Thursday, with news that U.S. tariffs will be capped at up to 15% — but a muted market reaction appeared to reflect skepticism among investors on whether the rate is set in stone. Fresh details on the European Union’s trade agreement with the White House revealed that […]
Read More
FDA approves first-ever glucose monitoring system for weight loss from Signos
Woman with Signos wearable and app Source: Signos The Food and Drug Administration on Wednesday approved the first-ever glucose monitoring system specifically for weight loss from the startup Signos, establishing a new option for Americans to manage their weight. Current treatment options for losing weight – popular drugs like GLP-1s and surgical interventions – are […]
Read More
Viking Therapeutics shares fall more than 30% on disappointing obesity pill trial data
Shares of Viking Therapeutics fell more than 30% in premarket trading Tuesday after the company released mid-stage trial data on its obesity pill that disappointed investors. The results could be a blow to Viking, which was once seen as a hot M&A target as pharmaceutical companies scramble to join the booming market for obesity and […]
Read More
Stocks making the biggest moves midday: Meta Platforms, Duolingo, Target, Dayforce, TeraWulf and more
Check out some of the companies making the biggest moves midday: Meta Platforms — The parent of Instagram and Facebook is planning the fourth overhaul of its artificial intelligence operations in six months , The Information reported late Friday, according to Reuters. Meta fell nearly 3% Monday. TeraWulf — The bitcoin miner and AI computing […]
Read More
Stocks making the biggest moves premarket: Dayforce, Sunrun, Tesla, Novo Nordisk and more
Check out the companies making headlines in premarket trading: Dayforce — The software stock surged more than 24% after people familiar with the matter told Bloomberg that Thoma Bravo is currently engaged in talks to acquire Dayforce and could do so in the coming weeks. Sunrun — Stock in the solar panel company gained 4%. […]
Read More
Eli Lilly’s 170% UK price hike for Mounjaro is just the start as pharma firms bow to Trump’s pricing pressures
Key Points Pharma giants are navigating U.S. President Donald Trump’s demands to bring U.S. drug prices in line with other developed nations. Eli Lilly’s decision to hike Mounjaro prices in the U.K. could spark similar moves from other firms, analysts say. The U.S. consistently pays the most in the world for many prescription drugs. Eli Lilly ‘s […]
Read More
Novo Nordisk offers diabetes drug Ozempic for less than half the price for cash-paying U.S. patients
A box of Ozempic made by Novo Nordisk, at a pharmacy in London on March 8, 2024. Hollie Adams | Reuters Novo Nordisk on Monday said it now offers cash-paying U.S. patients its blockbuster diabetes treatment Ozempic for less than half its monthly list price, as drugmakers face mounting political pressure to lower prices in […]
Read More
Novo Nordisk shares pop 5% after Wegovy receives U.S. approval for liver disease
Wegovy injection pens arranged in Waterbury, Vermont, US, on Monday, April 28, 2025. Shelby Knowles | Bloomberg | Getty Images Shares of Novo Nordisk climbed almost 5% Monday after the company’s blockbuster Wegovy obesity drug received accelerated approval from the U.S. Food and Drug Administration to treat a serious liver disease. The company on Friday […]
Read More
Eli Lilly’s obesity pill led to around 12% weight loss in closely watched late-stage trial, paving way for approval
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly on Thursday said the highest dose of its daily obesity pill helped patients lose almost 12% of their body weight, or roughly 27 pounds, at 72 weeks in […]
Read More
Eli Lilly earnings are coming Thursday. Here’s what top analysts expect
Many on Wall Street expect that Novo Nordisk ‘s loss has been Eli Lilly ‘s gain, and this will be good news for the Zepbound maker’s second-quarter results. Novo Nordisk’s stock has cratered about 47% since the start of the year, as doubts emerged about the outlook for its GLP-1 drugs, Ozempic for diabetes and […]
Read More